158 related articles for article (PubMed ID: 7192426)
21. 6-diazo-5-oxo-L-norleucine and azaserine as affinity inhibitors of glutamin(asparagin)ase.
Lebedeva ZI; Kabanova EA; Berezov TT
Biochem Int; 1986 Mar; 12(3):413-20. PubMed ID: 3707592
[TBL] [Abstract][Full Text] [Related]
22. Uptake of glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and acivicin in sensitive and resistant tumor cell lines.
Huber KR; Rosenfeld H; Roberts J
Int J Cancer; 1988 May; 41(5):752-5. PubMed ID: 3366493
[TBL] [Abstract][Full Text] [Related]
23. Use of 6-diazo-5-oxo-L-norleucine to study interaction between myocardial glycoconjugate secretion and endothelial activation in the early embryonic chick heart.
Markwald RR; Funderburg FM
Dev Biol; 1983 Oct; 99(2):395-407. PubMed ID: 6618009
[TBL] [Abstract][Full Text] [Related]
24. Corneal geometry: an alternative explanation of the effect of 6-diazo-5-oxo-l-norleucine on the development of chick cornea.
Gordon H
Dev Biol; 1976 Oct; 53(2):303-5. PubMed ID: 992212
[No Abstract] [Full Text] [Related]
25. Avian corneal innervation: inhibition of nerve ring formation by 6-diazo-5-oxo-L-norleucine.
Bee JA; Unruh NC; Sommerfeld DL; Conrad GW
Dev Biol; 1982 Jul; 92(1):123-32. PubMed ID: 7106373
[No Abstract] [Full Text] [Related]
26. N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders.
Nedelcovych MT; Tenora L; Kim BH; Kelschenbach J; Chao W; Hadas E; Jančařík A; Prchalová E; Zimmermann SC; Dash RP; Gadiano AJ; Garrett C; Furtmüller G; Oh B; Brandacher G; Alt J; Majer P; Volsky DJ; Rais R; Slusher BS
J Med Chem; 2017 Aug; 60(16):7186-7198. PubMed ID: 28759224
[TBL] [Abstract][Full Text] [Related]
27. Detection of antigens on mouse giant trophoblast cells after incubation with an inhibitor of glycoprotein synthesis.
Carter J
J Reprod Fertil; 1981 Sep; 63(1):155-62. PubMed ID: 7277313
[TBL] [Abstract][Full Text] [Related]
28. Glutaminase inhibition and the release of neurotransmitter glutamate from synaptosomes.
Bradford HF; Ward HK; Foley P
Brain Res; 1989 Jan; 476(1):29-34. PubMed ID: 2563333
[TBL] [Abstract][Full Text] [Related]
29. Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor.
Gao RD; Hin N; Prchalová E; Pal A; Lam J; Rais R; Slusher BS; Tsukamoto T
Bioorg Med Chem Lett; 2021 Oct; 50():128321. PubMed ID: 34400301
[TBL] [Abstract][Full Text] [Related]
30. Mutagenicity of D- and L-azaserine, 6-diazo-5-oxo-L-norleucine and N-(N-methyl-N-nitroso-carbamyl)-L-ornithine in the Salmonella test system.
Staiano N; Everson RB; Cooney DA; Longnecker DS; Thorgeirsson SS
Mutat Res; 1980 Dec; 79(4):387-90. PubMed ID: 7003378
[No Abstract] [Full Text] [Related]
31. Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON).
Rahman A; Smith FP; Luc PT; Woolley PV
Invest New Drugs; 1985; 3(4):369-74. PubMed ID: 4086244
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase.
Rosenfeld H; Roberts J
Cancer Res; 1981 Apr; 41(4):1324-8. PubMed ID: 7214322
[TBL] [Abstract][Full Text] [Related]
33. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.
Lynch G; Kemeny N; Casper E
Am J Clin Oncol; 1982 Oct; 5(5):541-3. PubMed ID: 7180833
[TBL] [Abstract][Full Text] [Related]
34. Inactivation of renal gamma-glutamyl transferase by 6-diazo-5-oxo-L-norleucylglycine, an inactive precursor of affinity-labeling reagent.
Inoue M; Morino Y
Proc Natl Acad Sci U S A; 1981 Jan; 78(1):46-9. PubMed ID: 6113588
[TBL] [Abstract][Full Text] [Related]
35. Formation of concentric saccules in murine parietal cells after injection of diazo-oxo-norleucine.
Michaels JE
Anat Rec; 1979 Apr; 193(4):775-90. PubMed ID: 218477
[TBL] [Abstract][Full Text] [Related]
36. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
Lemberg KM; Vornov JJ; Rais R; Slusher BS
Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
[TBL] [Abstract][Full Text] [Related]
37. Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine.
Wang SZ; Poore B; Alt J; Price A; Allen SJ; Hanaford AR; Kaur H; Orr BA; Slusher BS; Eberhart CG; Raabe EH; Rubens JA
Clin Cancer Res; 2019 Oct; 25(19):5925-5936. PubMed ID: 31300448
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia.
Lyons SD; Sant ME; Christopherson RI
J Biol Chem; 1990 Jul; 265(19):11377-81. PubMed ID: 2358467
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children.
Sullivan MP; Nelson JA; Feldman S; Van Nguyen B
Cancer Chemother Pharmacol; 1988; 21(1):78-84. PubMed ID: 3342470
[TBL] [Abstract][Full Text] [Related]
40. Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis.
Pham K; Maxwell MJ; Sweeney H; Alt J; Rais R; Eberhart CG; Slusher BS; Raabe EH
J Neuropathol Exp Neurol; 2021 Mar; 80(4):336-344. PubMed ID: 33712838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
